Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant bivalent COVID-19 vaccine - Beijing Health Guard Biotechnology

Drug Profile

Recombinant bivalent COVID-19 vaccine - Beijing Health Guard Biotechnology

Latest Information Update: 03 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Health Guard Biotechnology
  • Class COVID-19 vaccines; Peptide vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 06 Jan 2023 Beijing Health Guard Biotechnology announces intention to file Clinical Trial Application for COVID-2019 infections (prevention) in China in the second quarter of 2022 (Beijing Health Guard Biotechnology website, January 2023)
  • 27 Sep 2022 Preclinical trials in COVID-2019 infections (Prevention) in China (Parenteral), prior to September 2022 (Beijing Health Guard Biotechnology pipeline, January 2023) (https://www.klws.com/Index/news/news_info/id/32.html)
  • 27 Sep 2022 Beijing Health Guard Biotechnology receives Ethical Approval Letter to commence a phase I trial for COVID-2019 infections (Prevention) in overseas (South Africa) (https://www.klws.com/Index/news/news_info/id/32.html)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top